drugset / Trial / NCT06351527
Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ICP-248 as Monotherapy or in Combination With Anti-CD20 Monoclonal Antibody in Mature B-cell Malignancies
Non-randomizedSingle-groupOpen-labelTreatment
Summary
Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of ICP-248 as monotherapy or in combination with anti-CD20 monoclonal antibody in Mature B-cell Malignancies
Timeline
- Start
- 2024-04-23
- Primary completion
- 2027-06-25
- Completion
- 2027-10-25
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ICP-248 | Unknown | 5 mg | Oral |
| Subject | ICP-248 | Unknown | 10 mg | Oral |
| Subject | ICP-248 | Unknown | 150 mg | Oral |
| Subject | Obinutuzumab | Monoclonal antibody | 100 mg | Intravenous |
| Subject | Obinutuzumab | Monoclonal antibody | 1000 mg | Intravenous |
| Subject | Rituximab | Monoclonal antibody | 375 mg/m2 | Intravenous |